Prostate Cancer VL

Best Use of "Old and Cheap” Drugs- Ian F. Tannock

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Pharmacokinetics and Tolerance of Prostate Cancer Drugs in Japan and Other Asian countries - Hiroyoshi Suzuki

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

PSMA PET in Prostate Cancer: Steve Cho

Details
Prostate-specific membrane antigen (PSMA) has received a resurgence of attention as a useful biomarker in the imaging evaluation of prostate cancer with PET. Philip Koo, MD, welcomes Steve Cho, MD to discuss PSMA PET in prostate cancer for the inaugural lecture for the Imaging Center of Excellence on UroToday. Dr. Cho's discusses the number of agents that are being developed in prostate cancer and...

Welcome Address from Silke Gillessen and Aurelius Omlin at the Advanced Prostate Cancer Consensus Conference

Details
The co-founders of the 2017 Advanced Prostate Cancer Consensus Conference (APCCC), Silke Gillessen and Aurelius Omlin, discuss with Neal Shore different learnings from the 2015 APCCC and how it prepared them for the 2017 meeting. In addition, discussion on the number of countries that are represented and different types of specialists that attended the conference this year. The concept of the modi...

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide in the High-risk Nonmetastatic Castration-resistant Prostate Cancer - Charles Ryan

Details
Journal Club: Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. European Urology Charles Ryan, MD discusses the androgen receptor antagonist apalutamide was safe in patients with high-risk nonmetastatic castration-resistant prostate cancer and, based on dura...

Imaging of Metastatic Prostate Cancer- Anwar Padhar

Details
This video lecture presentations took place at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), in Lisbon, Portugal between in October 2016. The meeting was organised by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal. Anwar Padhar, MD, discusses the impact of imaging in diagnosing metastatic prosta...

Predicting survival of men with prostate cancer after radical prostatectomy- Axel Merseburger

Details
The presentations listed here were made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October. Dr. Axel Merseburger presentation on predicting survival of men with prostate cancer after radical prostatectomy reviews the traditional pre-operative predictors in addition to the combination of pre and post operative clin...

Prevalence of Cardiovascular Disease in Patients with Prostate Cancer- Alexander Lyon

Details
The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October. Dr. Alexander Lyon discusses the high cardiovascular events in prostate cancer patients and the GnRH agonists associated with elevated risk of CV events and GnRH antagonists has less toxicity in retrospective analysis. Dr. Lyon...

Point- CounterPoint: Are Novel Biomarkers Ready For Primetime in Routine Detection of Prostate Cancer? -Badrinath Konety

Details
Dr. David Crawford invites Dr. Badrinath Konety to provide a counterpoint discussion on novel biomarkers and their use in detecting prostate cancer. Although, Dr. Konety agrees with the value of biomarkers and that they can be used in addition to PSA tests, he is not sure they are ready for prime time. Dr. Konety proposes key questions on novel biomarkers including their level improvement, are the...

Point - CounterPoint: Are Novel Biomarkers Ready For Primetime in Routine Detection of Prostate Cancer?- Scott Eggener

Details
Dr. David Crawford invites Dr. Scott Eggener to participate in a point-counter point discussion on novel biomarkers in the detection of prostate cancer. Dr. Eggener lectures includes information on different biomarkers and reviews the data that supports his position that novel biomarkers are ready for prime time. Novel prostate cancer screening biomarkers preserve benefits of screening and dramati...